PERTH, AUSTRALIA: April 26, 2012 – Phylogica Ltd (ASX:PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that it has been granted a new patent (AU: 2007218045), by the Australian Patent Office. This worldwide patent (WIPO: WO200/097923) is pending in multiple other jurisdictions, including the USA, Europe and Japan. The patent covers methods of producing designed, synthetic libraries of peptides that are predicted to be rich in structure and, therefore, more likely to be drug-like than conventional random peptides.
There are numerous applications of the newly patented technology, including the rational design of Phylomer libraries in parallel formats on solid surfaces, such as peptide arrays or beads. Array formats enable tens of thousands of peptides to be screened against multiple targets on a single miniature ‘chip’, significantly reducing the time and cost of identifying relevant drug candidates. The technology is highly amenable to scaling using multiple chips to screen hundreds of thousands to millions of peptides at a time. The technology also enhances various value-added uses of the Company’s platform, including direct phenotypic screening of Phylomer libraries for the discovery of, for example, novel antivirals, antibiotics or anticancer agents. In addition, array formats facilitate the construction of a range of high-density Phylomer libraries, which can be used for new applications of the platform, such as the identification of disease biomarkers for the development of novel diagnostic products.
For further information please download PDF below:
